ACADIA PHARMACEUTICALS INC. Increase (Decrease) in Operating Liabilities
ACADIA PHARMACEUTICALS INC. (ACAD) reported Increase (Decrease) in Operating Liabilities of -$1.08 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLiabilities · last filed 2019-08-01
- ACADIA PHARMACEUTICALS INC. increase (decrease) in operating liabilities for the quarter ending 2019-06-30 was -$139.00K.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in operating liabilities for the quarter ending 2019-03-31 was -$938.00K.
| Period end | Increase (Decrease) in Operating Liabilities 3 month | Increase (Decrease) in Operating Liabilities 6 month |
|---|---|---|
| 2019-06-30 | -$139.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$1.08M 10-Q · filed 2019-08-01 |
| 2019-03-31 | -$938.00K 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |